Cooperative activity of cytotoxic chemotherapy with antiangiogenic thrombospondin-I peptides, ABT-526 in pet dogs with relapsed lymphoma

Keyphrases

• Thrombospondin-1 (TSP-1) 100%
• Antiangiogenic 100%
• Cytotoxic Chemotherapy 100%
• Relapsed Lymphoma 100%
• Pet Dogs 100%
• Cooperative Activity 100%
• Placebo 75%
• Non-Hodgkin Lymphoma 50%
• Time to Progression 50%
• Duration of Response 50%
• Chemotherapy 25%
• Prospective Randomized Trial 25%
• Apoptosis 25%
• Endothelial Cells 25%
• Treatment Response 25%
• Preclinical Trials 25%
• Thrombocytopenia 25%
• Randomized Placebo-controlled Trial 25%
• Mouse Tumor Model 25%
• Response Rate 25%
• Antiangiogenic Therapy 25%
• Response Time 25%
• Double-blind Trial 25%
• No Significant Difference 25%
• Neutropenia 25%
• Nonapeptides 25%
• Objective Response Rate 25%
• Gastroenteritis 25%
• Alanine Aminotransferase 25%
• Specific Toxicity 25%
• First Relapse 25%
• Toxicosis 25%
• Bristol-Myers Squibb 25%

Pharmacology, Toxicology and Pharmaceutical Science

• Lomustine 100%
• Cytotoxic Chemotherapy 100%
• Antiangiogenic 100%
• Pet Animal 100%
• Thrombospondin 100%
• Placebo 36%
• Nonhodgkin Lymphoma 27%
• Toxic Injury 9%
• Chemotherapy 9%
• Antiangiogenic Therapy 9%
• Cancer Model 9%
• Alanine Aminotransferase 9%
• Gastroenteritis 9%
• Nonapeptide 9%
• Thrombocytopenia 9%
• Neutropenia 9%

Veterinary Science and Veterinary Medicine

• Dog 100%
• Pet Animal 100%
• Non-Hodgkin Lymphoma 42%
• Cancer 28%
• Mouse 14%
• Alanine Transaminase 14%
• Toxic Injury 14%